Joenja is the first FDA‑approved oral selective PI3Kδ inhibitor for activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS). It is administered to patients aged 12 years and older, targeting the underlying immune signaling defect in APDS to address both immunodeficiency and immune dysregulation.